Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection

Current Opinion in HIV and AIDS

Volumn 10, Issue 5, 2015, Pages 348-354

  El Sherif, Omar ^a   Khoo, Saye ^b   Solas, Caroline ^c,d  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Antiretrovirals; Direct acting antivirals; Drug interactions; HIV HCV coinfection; Pharmacokinetics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; DACLATASVIR; DARUNAVIR PLUS RITONAVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DIRECT ACTING ANTIVIRUS AGENT; EFAVIRENZ; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LEDIPASVIR PLUS SOFOSBUVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ADVERSE DRUG REACTION; ADVERSE EFFECTS; COINFECTION; COMPLICATION; DRUG COMBINATION; DRUG INTERACTION; HEPATITIS C, CHRONIC; PROCEDURES; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 84942881341     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000185     Document Type: Review

References (28)

1. World Health Organisation Hepatitis C fact-sheet No. 164; updated April 2014. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 19 May 2015.
2. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 365:1445-1454.
3. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med 2013; 14:195-207.
4. Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008; 197:1558-1566.
5. Sherman KE, Thomas D, Chung RT. Human immunodeficiency and liver disease forum 2012. Hepatology 2014; 59:307-317.
6. Bow DAJ, Liu J, Kavetskaia O et al. A mechanistic nonclinical assessment of drug-drug interactions (metabolism and transporters) with the HCV regimen: ABT-450/r, Ombitasvir, and Dasabuvir. Poster Presentation: AASLD/EASL Special Conference on Hepatitis C; 12-13 September 2014; New York City, New York.
7. Menon R, Badri P, Khatri A et al. ABT-450/ritonavir+Ombitasvir+Dasabuvir: Drug Interactions Mediated by Transporters. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 19-21 May 2014; Washington, DC.
8. Abbvie Corporation. Viekerax 12.5 mg/75 mg/50 mg film-coated tablet. [Prescribing Information] Abbvie Ltd, Maidenhead, United Kingdom.
9. Abbvie Corporation. Exviera 250mg film-coated tablet. [Prescribing Information] Abbvie Ltd, Maidenhead, United Kingdom.
10. Menon R, Badri P, Wang T, et al. Drug-drug interaction profile of the all-oral hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir and dasabuvir. J Hepatol 2015; 63:20-29.
11. Kharti A, Wang T, Wang H et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, Ombitasvir, and Dasabuvir with emtricitabine + tenofovir, raltegrevir, rilpivirine and efavirenz. Abstract: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 5-9 September 2014; Washington, DC.
12. Khatri A, Wang T, Wang H, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, Ombitasvir, and Dasabuvir with HIV protease inhibitors. Abstract: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 5-9 September 2014; Washington, DC.
13. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomised trial. JAMA 2015; 313:1223-1231.
14. Mathias A. Clinical pharmacology of DAA's for HCV: what's new and what's in the pipeline. Abstract: 14th International Workshop on Clinical Pharmacology of HIV, Therapy Session; 22-24 April 2013; Amsterdam, The Netherlands.
15. Kirby B, Mathias A, Rossi S et al. No clinically significant interactions between GS-7977 and HIV antiretrovirals atripla, rilpivirine, darunavir or raltegrevir in healthy volunteers. Abstract No 1877: 63rd Annual Meeting of the American Association for the Study of Liver Disease; 9-12 November 2012; Boston, MA.
16. German P, Pang PS, West S et al. Drug interactions between direct-acting anti-HCV antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals. Abstract: 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 19-21 May 2014; Washington, DC.
17. German P, Garrison K, Pang PS et al. Drug interactions between the anti-HCV regimen Ledipasvir/Sofosbuvir and Ritonavir Boosted Protease Inhibitors plus FTC/TDF. Abstract: 22nd Conference on Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA.
18. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection. JAMA 2015; 313:1232-1239.
19. Naggie S, Cooper C, Saag M et al. Ledipasvir/Sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1: ION-4. Abstract: 22nd Conference on Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA.
20. Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10:596-606.
21. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz, and tenofovir. Antivir Ther 2013; 18:931-940.
22. Bristol-Myers Squibb Pharmaceutical Ltd. Daklinza film-coated tablets. [Prescribing Information]. BMS Ltd, Middlesex, United Kingdom.
23. Eley T, You X, Wang R et al. Daclatasvir: Overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs. Abstract: HIV DART; 9-12 December 2014; Miami, FL.
24. Wyles DL, Ruane P, Sulkowski M et al. Daclatasvir in combination with Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study. Abstract: 22nd Conference on Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA.
25. Ouwerkerk-Mahadevan S, Sekar V, Simion A et al. The pharmacokinetic ineractions of the HCV protease inhibitor TMC-435 with HIV antiretroviral agents in healthy volunteers. Abstract: Infectious Disease Society Association Conference; 17-21 October 2012; San Diego, CA.
26. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complication and mortality in patients co-infected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-413.
27. Gilead Sciences, Inc. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Revised 10/2014.
28. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2015.03.025. Accessed 19 May 2015.